In This Store
Category:Bio Products > Protein/Antigen/Polypeptide > Other Protein
Product Name:99% up by HPLC Tirzepatide 2023788-19-2
CAS No.:2023788-19-2
Standard:In-house Standards
Price(USD):Negotiable
Company:Sinoway Industrial Co. Ltd
Grade: Pharmaceutical Grade
Factory Location: Xiamen Fujian
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Monthly Production Capacity: 10ton/year
Packaging Information: 25kg/drum; 5kg/bag, 1kg/bag
Delivery Lead Time: 7 days after payment
Sample Provided: yes
Payment Terms: L/L
Product Information |
Product name |
Tirzepatide; TZP |
CAS No. |
2023788-19-2 |
Molecular Formula |
C225H348N48O68 |
Molecular Weight |
4813.45 |
Quality Standard |
99% up by HPLC, DMF |
Amino Acid Sequence |
Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-GIn-(diacid-C20-gamma-Glu-(AEEA)2-Lys)-Ala-Phe-Val-GIn-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
Appearance |
White powder |
COA |
Test Items |
Specifications |
Results |
Appearance |
White powder |
White powder |
Solubility |
Freely soluble in water, insoluble in acetonitrile. |
Conforms |
Color of solution and clarity |
The solution should be clear and colorless. |
Conforms
|
Specific optical rotation |
-19.0° - -39.0°(Calculated on anhydrous、 ion-free basis) |
-32.9° |
Identification |
HPLC chromatography: The retention time of the major peak of test solution corresponds to that of the reference solution, as obtain under Assay |
Conforms |
Monoisotopic mass: 4813.45±1 .0 |
4813.05 |
|
pH |
6.0-8.0 |
7.4 |
Water |
≤10.0% |
1.2% |
Sodium ion |
≤4.0% |
1.3% |
Ammonium ion |
≤0.5% |
ND |
Phosphate ion |
≤0.5% |
ND |
Trifluoroacetic acid |
≤1000ppm |
ND |
Acetic acid |
≤5000ppm |
ND |
High molecular weight species |
≤0.3% |
0.1% |
Residual solvents |
Triethylamine≤ 0.5% |
ND |
Methanol ≤ 3000ppm |
29ppm |
|
Isopropanol ≤ 5000ppm |
ND |
|
Acetonitrile ≤ 410ppm |
7ppm |
|
Dichloromethane ≤ 600ppm |
ND |
|
Methyl tert-butyl ether ≤ 5000ppm |
0 ppm |
|
N,N-dimethylformamide ≤ 880ppm |
ND |
|
Methanol ≤ 3000ppm |
270ppm |
|
Related substances |
Maximum single unknown impurity ≤ 0.5% |
0.32% |
Total impurities ≤ 2.0% |
0.51% |
|
Purity ≥ 98.0% |
99.5% |
|
Assay |
95.0 % - 105.0% (Calculated as the anhydrous, sodium ion-free, ammonium ion-free, phosphate ion-free substance) |
101.2% |
Peptide content |
≥ 85.0% |
97% |
Bacterial endotoxins |
≤ 10EU/mg |
<0.5EU/mg |
Microbial Limit |
Total aerobic microbial count ≤ 1000cfu/g |
< 10cfu/g |
Total molds and yeasts count ≤ 100cfu/g |
< 10cfu/g |
|
Total E.Coli can not be detected |
ND |
|
Amino acid ratio |
Asp 1.6-2.4 |
2.2 |
Tyr 1.6-2.4 |
1.7 |
|
Lys 1.6-2.4 |
2.4 |
|
Ile 2.4-3.6 |
2.6 |
|
Leu 1.6-2.4 |
2.0 |
|
Val 0.8-1.2 |
0.9 |
|
Thr 1.6-2.4 |
1.9 |
|
Phe 1.6-2.4 |
1.9 |
|
Ser 4.0-6.0 |
5.3 |
|
Ala 3.2-4.8 |
3.9 |
|
Gly 3.2-4.8 |
4.0 |
|
Glu 3.2-4.8 |
4.2 |
|
Trp detected |
Detected |
|
Pro 3.2-4.8 |
4.1 |
|
Aib 1.6-2.4 |
1.8 |
|
AEEA 1.6-2.4 |
1.8 |
|
Conclusion |
It conforms to all the requirements of enterprise. |
Usage |
1. Tirzepatide is the world's first dual GIP/GLP-1 receptor agonist. It exerts its therapeutic effects by simultaneously targeting two key receptors:
(1) Glucose-dependent insulinotropic polypeptide (GIP) receptor: Enhances insulin secretion and suppresses glucagon, improving glycemic control.
(2) Glucagon-like peptide-1 (GLP-1) receptor: Delays gastric emptying, increases satiety, and promotes glucose-dependent insulin release.
This dual mechanism provides synergistic metabolic benefits, demonstrating superior efficacy compared to single-target agents.
2. Indications of Tirzepatide:
Tirzepatide is approved for two primary indications:
(1) Type 2 diabetes: Marketed as Mounjaro®, clinical trials (SURPASS series) showed HbA1c reductions up to 2.4%, with some patients achieving normoglycemia.
(2) Obesity: Marketed as Zepbound®, FDA-approved in 2023 for chronic weight management in adults, with expansion to the Chinese market in 2024. Pivotal trials (SURMOUNT series) reported mean weight loss of 15%-22%, peaking at 24% (72-week regimen).
3. Key Advantages and Clinical Outcomes
Compared to single GLP-1 agonists (e.g., Novo Nordisk's semaglutide), Tirzepatide exhibits:
(1) Superior weight loss: Head-to-head trials demonstrated 5%-7% greater weight reduction at equivalent doses.
(2) Enhanced glycemic control: Greater improvement in insulin resistance, particularly for patients with obesity-complicated diabetes.
(3) Comparable tolerability: Similar incidence of common adverse effects (nausea, diarrhea) with rare severe events.
*Products under the patent are only for R&D use.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094
Follow Us: